HIPEC Combined With SOX and Sintilimab in the Treatment of Advanced Gastric Cancer With Peritoneal Metastasis

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

69

Participants

Timeline

Start Date

February 20, 2024

Primary Completion Date

May 30, 2027

Study Completion Date

June 30, 2027

Conditions
Peritoneal MetastasesGastric Cancer
Interventions
DRUG

S-1, Oxaliplatin sintilimab HIPEC

"1. Exploratory laparoscopy or laparotomy~2. SOX regimen (oxaliplatin 100mg/m2, d1, S-1 BSA\<1.25m2 40mg, twice a day; 1.25m2 ≤ BSA \< 1.5m2 50mg, twice a day; BSA ≥ 1.5m2 60mg, twice a day; d1-14) chemotherapy combined with sintilimab (200mg, d1), once every three weeks.~3. In the first cycle, HIPEC (paclitaxel 80 mg/m2, d1-d3) will be administrated,~4. In the second and third cycles, HIPEC or intraperitoneal chemotherapy (paclitaxel 80 mg/m2, d1) will be administrated according to the patient's condition.~5. Another 3-cycle SOX regimen of systemic chemotherapy.~6. After the end of 6 cycles, maintain treatment with a combination of S-1 and sintilimab until disease progression or intolerable toxicity."

All Listed Sponsors
lead

Sichuan University

OTHER

NCT06213519 - HIPEC Combined With SOX and Sintilimab in the Treatment of Advanced Gastric Cancer With Peritoneal Metastasis | Biotech Hunter | Biotech Hunter